STOCK TITAN
  1. Home
  2. Sec-filings
  3. CCCC
  4. [Form 4] C4 Therapeutics, Inc. Insider Trading Activity

CCCC insider: Director takes 6,740 shares as compensation at $2.15

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Donna Grogan, a non-employee director of C4 Therapeutics, Inc. (CCCC), received 6,740 shares of common stock on 10/01/2025 by electing to take equity in lieu of cash under the company’s Non-Employee Director Compensation Policy. The shares were recorded at a per-share price of $2.15, equal to the closing market price on the transaction date. After the grant, the reporting person beneficially owned 58,629 shares, held directly. The Form 4 discloses the transaction code and confirms the shares were issued as director compensation.

Positive

  • 6,740 shares issued under the Non-Employee Director Compensation Policy, indicating director alignment with shareholder interests
  • Transaction executed at closing market price of $2.15, reflecting a market-based issuance

Negative

  • None.

Insights

Director elected stock compensation, modest stake increase of 6,740 shares.

The disclosure shows a routine equity election under the issuer’s Non-Employee Director Compensation Policy, converting cash compensation into common stock at the market close price of $2.15. This is a non‑derivative, direct acquisition and increases the director’s reported beneficial ownership to 58,629 shares.

Such elections are common governance practice to align directors with shareholder outcomes and are informational for investors tracking insider ownership changes.

Insider GROGAN DONNA ROY
Role Director
Type Security Shares Price Value
Grant/Award Common Stock 6,740 $2.15 $14K
Holdings After Transaction: Common Stock — 58,629 shares (Direct)
Footnotes (1)
  1. These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2025.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
GROGAN DONNA ROY
(Last) (First) (Middle)
C/O C4 THERAPEUTICS, INC.
490 ARSENAL WAY #120
(Street)
WATERTOWN MA 02472
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/01/2025 A(1) 6,740 A $2.15(2) 58,629 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2025.
Remarks:
/s/ Jolie M. Siegel, Attorney-in-Fact 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did the CCCC Form 4 filed for Donna Grogan report?

The Form 4 reports that Donna Grogan acquired 6,740 shares of C4 Therapeutics common stock on 10/01/2025 as director compensation.

How was the 6,740 share grant priced in the CCCC Form 4?

The shares were recorded at $2.15 per share, which the Form states is the closing market price on the transaction date.

What is Donna Grogan’s beneficial ownership after the transaction for CCCC?

Following the reported transaction the Form 4 lists 58,629 shares beneficially owned by Donna Grogan (direct ownership).

Why were shares issued to Donna Grogan according to the filing?

The filing states the shares were issued because the reporting person elected to receive common stock in lieu of cash under the company’s Non-Employee Director Compensation Policy.

Is the reported transaction a derivative or non-derivative activity in the CCCC Form 4?

The transaction is a non-derivative acquisition of common stock (directly acquired shares), as shown in Table I of the Form 4.